
UAB startup NuVasc is advancing precision medicine for brain arteriovenous malformations
The survivor-founded company licensed liquid biopsy technology that identifies AVM-driving mutations, opening a path toward targeted therapies.
August 18

The survivor-founded company licensed liquid biopsy technology that identifies AVM-driving mutations, opening a path toward targeted therapies.